Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q5JZY3
UPID:
EPHAA_HUMAN
Alternative names:
-
Alternative UPACC:
Q5JZY3; A4FU89; J3KPB5; Q6NW42
Background:
Ephrin type-A receptor 10 plays a pivotal role in cellular communication, specifically binding to members of the ephrin-A family, including EFNA3, EFNA4, and EFNA5. This interaction is crucial for various developmental and physiological processes.
Therapeutic significance:
The receptor's involvement in Deafness, autosomal dominant, 88, characterized by progressive and severe postlingual hearing loss, highlights its potential as a target for therapeutic intervention. Understanding the receptor's role could lead to novel treatments for sensorineural hearing loss.